How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,063 results for

HIV Risk Screening Questions

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. A Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents (...) . In addition, ART treatment in pregnant persons living with HIV and use of other precautions substantially decrease the risk of transmission to the fetus, newborn, or infant. Abbreviations: ACOG=American College of Obstetricians and Gynecologists; AIDS=acquired immunodeficiency syndrome; ART=antiretroviral therapy; CDC=Centers for Disease Prevention and Control; HIV= human immunodeficiency virus; STI=sexually transmitted infection. For a summary of the evidence systematically reviewed in making

2019 U.S. Preventive Services Task Force

2. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

Once-daily oral treatment with combined tenofovir disoproxil fumarate and emtricitabine is the only formulation of PrEP currently approved by the US Food and Drug Administration for use in the United States in persons at risk of sexual acquisition of HIV infection. Relevant USPSTF Recommendations The USPSTF has issued recommendations on behavioral counseling to reduce risk of STIs and on screening for HIV infection. Abbreviations: HIV=human immunodeficiency virus; STI=sexually transmitted infection (...) Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Persons at high risk of HIV acquisition The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. A View the Clinical Summary in Population Persons at high risk of HIV acquisition

2019 U.S. Preventive Services Task Force

3. HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP)

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) © 2014 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline Background 2 Screening Recommendations HIV Test Ordering and Consent 2 Indications for Periodic HIV Screening 3 Referrals 3 Follow-up and Monitoring 4 Pre-Exposure Prophylaxis (PrEP) 4 Evidence Summary 5 References 6 Guideline Development Process (...) contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient. 2 Background Of the approximately 1.2 million people living with HIV (human immunodeficiency virus) in the United States, 20–25% are unaware that they are infected. In Washington State, about 12,000 people

2013 Kaiser Permanente Clinical Guidelines

4. Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations

advances in the prevention of perinatal transmission of human immunodeficiency virus (HIV), it is clear that early identification and treatment of all pregnant women with HIV is the best way to prevent neonatal infection and also improve women’s health. Furthermore, new evidence suggests that early initiation of antiretroviral therapy in the course of infection is beneficial for individuals infected with HIV and reduces the rate of sexual transmission to partners who are not infected. Screening should (...) be performed after women have been notified that HIV screening is recommended for all pregnant patients and that they will receive an HIV test as part of the routine panel of prenatal tests unless they decline (opt-out screening). Human immunodeficiency virus testing using the opt-out approach, which is currently permitted in every jurisdiction in the United States, should be a routine component of care for women during prepregnancy and as early in pregnancy as possible. Repeat HIV testing in the third

2018 American College of Obstetricians and Gynecologists

5. Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection

experienced in initiating and monitoring the continuation of prophylactic antiretroviral therapy for at-risk neonates and infants. Ideally this process should occur before delivery, but otherwise as soon as possible after birth. Management of Human Immunodeficiency Virus-infected Women With Prelabor Rupture of Membranes at Term Questions have surrounded the optimal management of HIV-infected women with prelabor rupture of membranes (also referred to as premature rupture of membranes) (PROM) at term (...) after Cesarian section in HIV-infected women. AIDS 1996;10:923–4. Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:661–7. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE. Risk factors for perinatal human immunodeficiency virus transmission

2018 American College of Obstetricians and Gynecologists

6. Routine Human Immunodeficiency Virus Screening

Routine Human Immunodeficiency Virus Screening Routine Human Immunodeficiency Virus Screening - ACOG Menu ▼ Routine Human Immunodeficiency Virus Screening Page Navigation ▼ Number 596, May 2014 (Replaces Committee Opinion Number 411, August 2008) (Reaffirmed 2019) Committee on Gynecologic Practice This Committee Opinion was developed with the assistance of the HIV Expert Work Group. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change (...) . This information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Routine Human Immunodeficiency Virus Screening Abstract: Early diagnosis and treatment of human immunodeficiency virus (HIV) can improve survival and reduce morbidity. The Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommend that females aged 13–64 years be tested at least once in their lifetime and annually thereafter based on factors

2014 American College of Obstetricians and Gynecologists

7. Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV (...) ) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjects From the LATTE Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03639311 Recruitment

2018 Clinical Trials

8. Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus

without HIV. However, co-infected patients may have a delay in resolution of symptoms and may require more prolonged therapy (24). Syphilis Women infected with HIV should be screened with syphilis testing at entry to care and at least annually thereafter. Interpretation of treponemal and nontreponemal serologic test results for syphilis does not differ between HIV-infected and noninfected women. Human immunodeficiency virus may be associated with a higher risk of false-positive nontreponemal serologic (...) to the institution or type of practice. Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus In the United States in 2013, there were an estimated 226,000 women and adolescents living with human immunodeficiency virus (HIV) infection ( ). Women with HIV are living longer, healthier lives, so the need for routine and problem-focused gynecologic care has increased. The purpose of this document is to educate clinicians about basic health screening and care, family planning, prepregnancy care

2016 American College of Obstetricians and Gynecologists

9. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2017 Clinical Trials

10. Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

will then be studied in Part B in a parallel design in two or more cohorts (depending upon the data obtained in Part A). Approximately 34 HIV-1 infected treatment-naive subjects will be enrolled during the study. Subjects in both parts will have a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose. Maximum duration of study participation will be approximately 6 Weeks. Condition or disease Intervention/treatment Phase Infection, Human Immunodeficiency Virus Drug (...) Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

11. Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03446573 Recruitment Status : Recruiting First Posted : February 27, 2018 Last Update Posted : November 28, 2018 See Sponsor: ViiV Healthcare Collaborator: GlaxoSmithKline Information provided by (Responsible Party): ViiV Healthcare Study Details Study Description Go to Brief Summary: The aim of the study is to establish if human immunodeficiency virus type 1 (HIV-1) infected adult subjects with current (...) Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2018 Clinical Trials

12. Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. Full Text available with Trip Pro

Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. Hepatitis C virus (HCV) is common in men who have sex with men (MSM) with HIV. The Swiss HCVree Trial targeted a micro-elimination by using a treat and counsel strategy. Self-reported condomless anal intercourse with non-steady partners was used as the selection criterion for participation in a counselling intervention designed to prevent HCV re (...) anal intercourse with non-steady partners during the prior year and calculated the sensitivity/specificity (95% CI) of the screening question in relation to the other at-risk behaviours.Seventy-two (61%) of the 118 men meeting eligibity criteria reported condomless anal intercourse with non-steady partners during the prior year. Many also engaged in other potential HCV transmission risk behaviours, e.g., 52 (44%) had used drugs. In participants disclosing drug use, 44 (37%) reported sexualised drug

2019 BMC Infectious Diseases

13. Syphilis Screening for Low-Risk Clients Visiting a Sexual Health Clinic: A focused practice question

Syphilis Screening for Low-Risk Clients Visiting a Sexual Health Clinic: A focused practice question Syphilis screening for low- risk clients visiting a sexual health clinic: A focused practice question Sue Fernane, Analyst, Research and Policy Barbara Fowler, Manager Healthy Sexuality Program Communicable Diseases Region of Peel Public Health November 2015 i Table of Contents Key Messages 2 1 Background 3 2 Literature Review Question 4 3 Literature Search 4 4 Relevance Assessment 5 5 Results (...) Sexuality clinical results. 4 While certain sexual behaviours or factors leading to a higher risk of acquiring syphilis are well documented in the literature, this focused practice question (FPQ) seeks to clarify the value and need for routine screening of all clients attending Peel sexual health clinics, including those at low risk of acquiring syphilis. Clients at lower risk for syphilis acquisition would include individuals that: are heterosexual with solely heterosexual partners, WSW (women who have

2016 Peel Health Library

14. Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients

Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients (Incorporate) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2015 Clinical Trials

15. HIV Risk Screening Questions

HIV Risk Screening Questions HIV Risk Screening Questions Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 HIV Risk Screening Questions (...) HIV Risk Screening Questions Aka: HIV Risk Screening Questions , High Risk Behavior Counseling , HIV Screening Questions From Related Chapters II. History: Questions regarding overall HIV risk What are you doing to put yourself at risk for HIV? What are the riskiest things that you are doing? If your were to be positive... How would you have become infected? When was the last time you put yourself at HIV risk? III. History: Questions about specific behaviors How do or drugs influence your HIV risk

2018 FP Notebook

16. Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations

susceptibility in the EU/EEA SCIENTIFIC ADVICE iv Abbreviations ANS Antenatal screening CRS Congenital rubella syndrome HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HIV Human immunodeficiency virus MMR Measles, mumps, rubella vaccine MTCT Mother-to-child transmission PICO (T) Population, intervention, comparison, outcome, time PWID People who inject drugs STI Sexually transmitted infection TESSy The European Surveillance System WHO World Health Organization SCIENTIFIC ADVICE Antenatal screening (...) implications for public health practice and research 1 1 Introduction 2 1.1 Objectives and target audience 2 1.2 Questions addressed 2 2 Background 3 2.1 Epidemiological and policy context in the EU/EEA 3 3 Guidance development 4 3.1 Member States survey 4 3.2 Literature reviews 4 3.2.1 Literature review on effectiveness and cost-effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility 4 3.2.2 Literature review on antenatal screening approaches that are effective

2017 European Centre for Disease Prevention and Control - Public Health Guidance

17. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

for HIV testing of adults, adolescents, and pregnant women in health-care settings. Available from: . Morbidity and Mortality Weekly Report: Recommendations and Reports. 2006;55(14):1–17. Accessed April 24, 2019. Austin T, Traversy GP, Ha S, Timmerman K. Canadian and international recommendations on the frequency of HIV screening and testing: A systematic review. Canada Communicable Disease Report. 2016;42(8):161–8. Public Health Agency of Canada (PHAC). Human immunodeficiency virusHIV screening (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

18. Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus Full Text available with Trip Pro

Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus To determine if better antiretroviral (ARV) central nervous system (CNS) penetration is associated with reduced rates of chronic pain in people living with HIV (PLWH).Chronic pain remains prevalent in PLWH despite widespread ARV use. Mechanisms underlying this prevalence remain unknown, though neuroinflammation from persistent CNS HIV infection (...) and maladaptive plastic changes in the CNS have been implicated. Here we hypothesize that better CNS ARV penetration, measured using the CNS Penetration-Effectiveness (CPE) score, would decrease rates of chronic pain.We interviewed 254 consecutive adults from an HIV clinic in Chiang Mai, Thailand. We collected data on demographics, HIV history, ARV use, and pain characteristics. Patients were evaluated for depression using a Thai two question Patient Health Questionnaire (PHQ-2). Modified CPE score

2016 Anti-infective agents

19. Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth Full Text available with Trip Pro

Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth Lesbian, gay, bisexual, transgender (LGBT), and questioning youth represent a diverse population who are affected by many sexual health inequities, including increased risk for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs). To provide comprehensive sexual health care for LGBT youth, providers should set the stage (...) with a nonjudgmental, respectful tone. Providers should be competent in recognizing symptoms of STIs and HIV and aware of the most up-to-date screening guidelines for LGBT youth. Sexual health visits should also focus on prevention, including safer sex practices, HIV pre-exposure and post-exposure prophylaxis, family planning, and immunization for hepatitis and human papillomavirus.Copyright © 2016 Elsevier Inc. All rights reserved.

2016 Pediatric Clinics Of North America

20. Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations

Congenital rubella syndrome ECDC European Centre for Disease Prevention and Control EEA European Economic Area EU European Union EEA European Economic Area HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HIV Human immunodeficiency virus IDU Intravenous drug use (user) LYG Life years gained LYS Life years saved MMR Measles, mumps, rubella vaccine MTCT Mother-to-child transmission PMTCT Prevention of mother-to-child transmission PICO Population, intervention, comparator, outcome PICO (T) Patient (...) 11. Excluded rubella studies 25 Table 12. Quality of evidence for rubella cohort studies using the CASP criteria [1] 25 Table 13. Economic assessment - screening of rubella susceptibility during pregnancy using Drummond checklist 25 Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations TECHNICAL REPORT iv Abbreviations AIDS Acquired immunodeficiency syndrome ANS Antenatal screening CASP Critical Appraisal Skills Programme CRS

2017 European Centre for Disease Prevention and Control - Literature Reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>